DOI: 10.3724/SP.J.1008.2011.00985

Academic Journal of Second Military Medical University (第二军医大学学报) 2011/31:9 PP.985-990

Zoledronic acid in preventing fractures in women with postmenopausal osteoporosis: a meta analysis

Objective To systematically analyze the studies investigating the outcomes of once-yearly administered intravenous zoledronic acid for preventing postmenopausal osteoporosis fracture. Methods Cochrane’s systematic review methods were used to retrieve the randomized controlled trials (RCT) about decreasing the risks of osteoporosis fracture in postmenopausal women by zoledronic acid from Cochrane Library, PubMed(Jan. 1966 to Apr. 2011), OVID(Jan. 1993 to Apr. 2011), EMBASE(Jan. 1974 to Apr. 2011), CNKI (Jan. 1979 to Apr. 2011), and VIP (Jan. 1989 to Apr. 2011) database. The studies were limited to human studies including bone fracture rates and follow-up for 2-3 years. All literatures identified from the data sources were evaluated for review inclusion, and the methodology of the included literatures was evaluated. Meta-analysis was performed using RevMan 5.0.25 software. Results Three randomized controlled studies met the inclusion criteria, including a total of 11 947 postmenopausal women with osteoporosis. Meta analysis results showed that zoledronic acid could reduce clinical vertebral fractures, hip fractures and nonvertebral-nonhip fractures by 75% (RR=0.25, 95%CI: 0.18-0.36), 33% (RR=0.67, 95%CI: 0.52-0.85), and 24% (RR=0.76, 95%CI: 0.67-0.87), respectively (P<0.05 for all comparisons). The incidence rates of serious adverse events were not significantly different between zoledronic acid group and placebo group. Conclusion Once-yearly intravenous injection of zoledronic acid (5 mg) can effectively prevent osteoporosis fracture in postmenopausal women without increasing the risk of serious adverse events.

Key words:zoledronic acid,postmenopausal osteoporosis,meta analysis,bone fractures

ReleaseDate:2014-07-21 16:00:10

[1] Sambrook P,Cooper C.Osteoporosis[J].Lancet,2006,367:2010-2018.

[2] Johnell O,Kanis J.Epidemiology of osteoporotic fractures[J].Osteoporos Int,2005,16(Suppl 2):S3-S7.

[3] Stevenson M,Jones M L,De Nigris E,Brewer N,Davis S,Oakley J.A systematic review and economic evaluation of alendronate,etidronate,risedronate,raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis[J].Health Technol Assess,2005,9:1-160.

[4] Wellington K,Goa K L.Zoledronic acid:a review of its use in the management of bone metastases and hypercalcaemia of malignancy[J].Drugs,2003,63:417-437.

[5] McClung M,Miller P,Recknor C,Mesenbrink P,Bucci-rechtweg C,Benhamou C L.Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass:a randomized controlled trial[J].Obstet Gynecol,2009,114:999-1007.

[6] Higgins J P T,Green S.Cochrane Handbook for Systematic Reviews of Interventions,Version 5.0.2[EB/OL].(2009-09) [2011-03-01].http://

[7] Hwang J S,Chin L S,Chen J F,Yang T S,Chen P Q,Tsai K S,et al.The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis[J].J Bone Miner Metab,2011,29:328-333.

[8] Black D M,Delmas P D,Eastell R,Reid I R,Boonen S,Cauley J A,et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J].N Engl J Med,2007,356:1809-1822.

[9] Boonen S,Black D M,Colón-emeric C S,Eastell R,Magaziner J S,Eriksen E F,et al.Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older[J].J Am Geriatr Soc,2010,58:292-299.

[10] Ensrud K E,Ewing S K,Taylor B C,Fink H A,Stone K L,Cauley J A,et al.Frailty and risk of falls,fracture,and mortality in older women:the study of osteoporotic fractures[J].J Gerontol A Biol Sci Med Sci,2007,62:744-751.

[11] Reid I R,Brown J P,Burckhardt P,Horowitz Z,Richardson P,Trechsel U,et al.Intravenous zoledronic acid in postmenopausal women with low bone mineral density[J].N Engl J Med,2002,346:653-661.

[12] Reid D M,Devogelaer J P,Saag K,Roux C,Lau C S,Reginster J Y,et al.Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis(HORIZON):a multicentre,double-blind,double-dummy,randomised controlled trial[J].Lancet,2009,373:1253-1263.

[13] Eriksen E F,Lyles K W,Colón-emeric C S,Pieper C F,Magaziner J S,Adachi J D,et al.Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture[J].J Bone Miner Res,2009,24:1308-1313.

[14] Eastell R,Black D M,Boonen S,Adami S,Felsenberg D,Lippuner K,et al.Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density[J].J Clin Endocrinol Metab,2009,94:3215-3225.

[15] Lyles K W,Col n-emeric C S,Magaziner J S,Adachi J D,Pieper C F,Mautalen C,et al.Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture[J].N Engl J Med,2007,357:nihpa40967.

[16] Reid I R,Gamble G D,Mesenbrink P,Lakatos P,Black D M.Characterization of and risk factors for the acute-phase response after zoledronic acid[J].J Clin Endocrinol Metab,2010,95:4380-4387.

[17] Reid D M.Update on the use of zoledronic acid in the management of osteoporosis[J].Curr Osteoporos Rep,2010,8:145-150.

[18] Hosking D,Lyles K,Brown J P,Fraser W D,Miller P,Curiel M D,et al.Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate[J].J Bone Miner Res,2007,22:142-148.

[19] Reid I R,Miller P,Lyles K,Fraser W,Brown J P,Saidi Y,et al.Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease[J].N Engl J Med,2005,353:898-908.